This study evaluates second-eye treatment with the AAV5-hRKp.RPGR gene therapy in participants previously treated for X-linked retinitis pigmentosa, an inherited eye disease. People who were treated in the earlier MGT009 study and enrolled in Study MGT010 may take part. It is a Phase 2 study that is currently active but not recruiting new participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Have been treated with AAV5-hRKp.RPGR in study MGT009 and have completed or is currently enrolled in Study MGT010 * Must sign an informed consent form indicating that they understand the purpose and procedures of the study and is willing to participate in the study * Willing to adhere to the protocol and long-term follow-up Exclusion Criteria: \- There are no specific exclusion criteria to enroll in this study